📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. The Module 3 (Quality / CMC) index and overview tying together the drug substance, drug product, and supporting quality sections.
Why it exists. Module 3 proves the drug can be made consistently, purely, and stably. This index orients a reviewer to the S (substance), P (product), and appendix/regional sections that follow.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH M4Q(R1) (CTD Quality) · Q6B · Q5C · Q3A/B · Q11
| Field | Value |
|---|---|
| Document ID | M3 |
| Version | 1.0 |
| Compound | GLPI-103 (GLP-1/APJ dual agonist peptide) |
| Standard | ICH M4Q(R1) (CTD Quality) · Q6B · Q5C · Q3A/B · Q11 |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]No CMC wet-lab data are generated by this project. This module presents a scientifically coherent, guideline-structured Quality narrative for a synthetic peptide with two drug products (IV solution, oral tablet). All specifications/values are illustrative.
No comments yet. Be the first to say something!
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | CMC / Quality | Initial version (knowledge-based mock) |
[MOCK]Primary structure (peptide mapping, MS, amino-acid analysis, sequencing), higher-order structure (CD, NMR as applicable), and impurity characterization (deletion/insertion sequences, oxidation, aggregation/dimers). Biological activity by GLP-1R and APJ potency assays.
| Attribute | Method | Acceptance (illustrative) |
|---|---|---|
| Identity | RP-HPLC retention + MS | Conforms |
| Assay (content) | RP-HPLC | 95.0–105.0% |
| Related substances | RP-HPLC | Any single ≤0.5%; total ≤2.0% |
| Aggregates | SEC | ≤1.0% |
| Counterion / water | IC / KF | Within limits |
| Bacterial endotoxin | LAL | ≤ limit (parenteral) |
| Bioburden | Compendial | ≤ limit |
Analytical procedures validated per Q2(R2). Batch analyses and specification justification provided.
Qualified primary and working reference standards with characterization and requalification protocol.
Drug substance stored in qualified containers (e.g., HDPE/foil) protecting from moisture/light.
Long-term (−20 °C) and accelerated stability support the retest period; stability-indicating methods (RP-HPLC, SEC) demonstrate control of degradation (oxidation, aggregation). [MOCK]
Two products are developed: P-IV (solution for IV infusion, once-weekly) and P-Oral (immediate-release tablet with permeation enhancer, once-daily).
Compendial excipients; the permeation enhancer controlled to its own specification.
| Attribute | P-IV | P-Oral |
|---|---|---|
| Appearance | Clear solution | Tablet, defined |
| Identity / Assay | RP-HPLC, 95–105% | RP-HPLC, 95–105% |
| Related substances | RP-HPLC | RP-HPLC |
| Dissolution | n/a | Q ≥80% at defined time |
| Uniformity of dosage units | — | Conforms |
| Sterility / Endotoxin | Conforms / ≤ limit | n/a |
| pH / Particulates | Within limits | n/a |
As per 3.2.S.5.
ICH-condition studies (long-term/accelerated) support shelf life and storage statements; stability-indicating methods confirm control of degradation. [MOCK]
Facilities and equipment; adventitious-agents safety (peptide synthetic origin minimizes viral/TSE risk; any animal-derived raw materials controlled).
Region-specific quality information for FDA/EMA/MFDS (e.g., executed batch records, method validation packages, comparability) provided per regional requirements.